GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Interest Coverage

Neurocrine Biosciences (Neurocrine Biosciences) Interest Coverage : 136.64 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Neurocrine Biosciences's Operating Income for the three months ended in Dec. 2023 was $150 Mil. Neurocrine Biosciences's Interest Expense for the three months ended in Dec. 2023 was $-1 Mil. Neurocrine Biosciences's interest coverage for the quarter that ended in Dec. 2023 was 136.64. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Neurocrine Biosciences Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Neurocrine Biosciences's Interest Coverage or its related term are showing as below:

NBIX' s Interest Coverage Range Over the Past 10 Years
Min: 1.36   Med: 9.98   Max: No Debt
Current: 82.25


NBIX's Interest Coverage is ranked better than
77.31% of 692 companies
in the Drug Manufacturers industry
Industry Median: 11.925 vs NBIX: 82.25

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Neurocrine Biosciences Interest Coverage Historical Data

The historical data trend for Neurocrine Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Neurocrine Biosciences Interest Coverage Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.08 9.98 8.05 35.07 85.83

Neurocrine Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.00 27.00 49.07 128.36 136.64

Competitive Comparison of Neurocrine Biosciences's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Interest Coverage falls into.



Neurocrine Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Neurocrine Biosciences's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Neurocrine Biosciences's Interest Expense was $-5 Mil. Its Operating Income was $395 Mil. And its Long-Term Debt & Capital Lease Obligation was $258 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2023 )/Interest Expense (A: Dec. 2023 )
=-1*394.8/-4.6
=85.83

Neurocrine Biosciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Neurocrine Biosciences's Interest Expense was $-1 Mil. Its Operating Income was $150 Mil. And its Long-Term Debt & Capital Lease Obligation was $258 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*150.3/-1.1
=136.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Neurocrine Biosciences  (NAS:NBIX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Neurocrine Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Executives
Kevin Charles Gorman officer: Sr VP, Business Development 12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter director 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano officer: Chief Business Dev Officer NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts officer: Chief Medical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke officer: Chief Human Resources Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons director, officer: President and CEO 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt officer: Chief Legal Officer C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia officer: Chief Scientific Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer officer: Chief Corp. Affairs Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet officer: Chief Regulatory Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy officer: Chief Financial Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich officer: Chief Commerical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith officer: Chief Regulatory Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080